Herborium Group Completes OTC Markets' Information Compliance
October 19 2010 - 8:54AM
Herborium Group, Inc., (Pink Sheets:HBRM) www.herborium.com, a
Botanical Therapeutics™ company, today announced it has filed all
Pink OTC® Market requirements to qualify as a company with Current
Information available on pinksheets.com – the highest tier
attainable for a Pink Sheets listed company.
"I am pleased our regulatory compliance initiative has
successfully filed all required OTC Market documents to raise our
tier status to Current Information," commented Dr. Agnes P.
Olszewski, Herborium Group's president and chief executive officer.
"We expect to continue our regulatory compliance initiative to
achieve a Bulletin Board reporting status as soon as it is
practical. I will update shareholders on this initiative as we
progress."
Herborium develops and licenses proprietary, all natural
botanically based medicines. The Company's differential advantage
is its ability to distinguish its Botanical Therapeutics® through
clinical-trial validation, which confirms their safety and
efficacy. The Company plans to capitalize on recent U.S. Food &
Drug Administration (FDA) guidelines (FDA Guidance for Industry:
Botanical Drug Products), which enable the advertising of its
products' medical claims.
AcnEase®, the Company's flagship product, is a proprietary,
systemically acting Botanical Therapeutic targeting acne and
rosacea in both females and males of all ages. AcnEase has proven
safe and effective through rigorous clinical testing.
(www.acnease.com).
"With the opinion letter regarding completeness of disclosure
posted, Pink OTC Markets will now verify that quarterly and annual
reports have been posted per its policies. We expect this
verification of our filings to help build investor confidence in
our public reporting. We also look forward to soon sharing with
investors the Company's new marketing strategy to gain a
significant share of the world's natural medicines market,"
Olszewski concluded.
About Herborium Group, Inc.
Herborium Group, Inc., a Botanical Therapeutics® company,
focuses on developing, licensing, and marketing proprietary,
botanically based medicinal products to consumers and healthcare
professionals. The Company's business model focuses on emerging
market opportunities spearheaded by the growth of a new market
sector located between high-cost, high-risk, ethical
pharmaceuticals and commoditized classic nutraceuticals
(supplements). The Company uses clinical validation and a
proactive regulatory strategy based on the FDA Guidance for
Industry: Botanical Drug Products (FDA Guidance 2004) to establish
and maintain a differential advantage. For more information, please
visit www.herborium.com and www.acnease.com.
One of our most important responsibilities is to communicate
with shareholders in an open and direct manner. Comments are
based on current management expectations, and are considered
"forward-looking statements," generally preceded by words such as
"plans," "expects," "believes," "anticipates," or
"intends." We cannot promise future returns. Our
statements reflect our best judgment at the time they are issued,
and we disclaim any obligation to update or alter forward-looking
statements as the result of new information or future
events. The Company urges investors to review the risks and
uncertainties contained within its filings with the OTC Markets
and/or Securities and Exchange Commission.
CONTACT: Herborium Group, Inc.
Dr. Agnes P. Olszewski, President & CEO
(201) 647-3757
Herborium (PK) (USOTC:HBRM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Herborium (PK) (USOTC:HBRM)
Historical Stock Chart
From Jul 2023 to Jul 2024